Nisa Investment Advisors
HRTX icon

Nisa Investment Advisors’s Heron Therapeutics HRTX Stock Holding History

Nisa Investment Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,456
Closed -$3.01K – 3030
2025
Q2 		$3.01K Buy
1,456
+400
+38% +$817 ﹤0.01% 2528
2025
Q1 		$2.32K Buy
1,056
+956
+956% +$1.85K ﹤0.01% 2430
2024
Q4 		$153 Sell
100
-106
-51% -$172 ﹤0.01% 2968
2024
Q3 		$410 Sell
206
-93
-31% -$222 ﹤0.01% 2756
2024
Q2 		$1.05K Buy
299
+135
+82% +$415 ﹤0.01% 2507
2024
Q1 		$454 Buy
164
+64
+64% +$161 ﹤0.01% 2515
2023
Q4 		$170 Sell
100
-985
-91% -$1.08K ﹤0.01% 2578
2023
Q3 		$1.12K Hold
1,085
– – ﹤0.01% 2384
2023
Q2 		$1.26K Sell
1,085
-100
-8% -$178 ﹤0.01% 2404
2023
Q1 		$2K Buy
1,185
+33
+3% +$83 ﹤0.01% 2322
2022
Q4 		$3K Buy
1,152
+67
+6% +$216 ﹤0.01% 2338
2022
Q3 		$4K Hold
1,085
– – ﹤0.01% 2319
2022
Q2 		$3K Sell
1,085
-56,200
-98% -$226K ﹤0.01% 2318
2022
Q1 		$328K Buy
57,285
+56,200
+5,180% +$411K ﹤0.01% 1204
2021
Q4 		$9K Sell
1,085
-8,704
-89% -$88.9K ﹤0.01% 2041
2021
Q3 		$105 Buy
9,789
+4,604
+89% +$56.1K ﹤0.01% 1675
2021
Q2 		$80 Hold
5,185
– – ﹤0.01% 1800
2021
Q1 		$84 Hold
5,185
– – ﹤0.01% 1822
2020
Q4 		$110K Buy
5,185
+950
+22% +$16.5K ﹤0.01% 1695
2020
Q3 		$63K Buy
4,235
+3,400
+407% +$53K ﹤0.01% 1711
2020
Q2 		$12K Buy
835
+95
+13% +$1.56K ﹤0.01% 1882
2020
Q1 		$9K Buy
740
+270
+57% +$5.08K ﹤0.01% 1866
2019
Q4 		$11K Hold
470
– – ﹤0.01% 1808
2019
Q3 		$9K Buy
470
+160
+52% +$2.94K ﹤0.01% 1807
2019
Q2 		$6K Hold
310
– – ﹤0.01% 1862
2019
Q1 		$8K Hold
310
– – ﹤0.01% 1819
2018
Q4 		$8K Hold
310
– – ﹤0.01% 1700
2018
Q3 		$10K Buy
+310
New +$11.5K ﹤0.01% 1728

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nisa Investment Advisors's HRTX Position: Q3 2025 in Review

Nisa Investment Advisors sold out of Heron Therapeutics (HRTX) in Q3 2025, closing a stake of 1,456 shares — an estimated $3.01K sold.

Nisa Investment Advisors first reported a position in HRTX in Q3 2018 and held it in 28 quarters. The position peaked at $328K in Q1 2022. 172 funds tracked by Wall St. Rank hold HRTX as of Q3 2025.

  • Nisa Investment Advisors reported no remaining Heron Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Nisa Investment Advisors sold 1,456 Heron Therapeutics shares in Q3 2025, an estimated $3.01K.
  • Nisa Investment Advisors first reported a position in Heron Therapeutics in Q3 2018 and held it in 28 quarters.
  • Nisa Investment Advisors's Heron Therapeutics position peaked at $328K in Q1 2022.
  • 172 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2025.

Based on Nisa Investment Advisors's 13F filing for Q3 2025, filed 23 Oct 2025.